Lupin launches Penicillamine Tablets USP after receiving USFDA approval

Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S.

Mar 02, 2021 03:03 IST India Infoline News Service

Global pharma major Lupin Limited (Lupin) has announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S. 

Lupin Ltd was currently trading at Rs1,054.55 per piece up by Rs32 or 3.13% from its previous closing of Rs1,022.55 per piece on the BSE, at around 3:10 PM

Related Story

Explore Important Blogs